Vertex Pharmaceuticals Inc

NASDAQ:VRTXUnited States

Today

Show headlines and story abstract

• DJ Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings, from 3 hours ago by Dow Jones

  3 hours ago by Dow Jones
  Companies Mentioned: VRTX
  
  By Sabela Ojea
  
  Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter.
  
  The biotechnology company on Monday posted a quarterly net profit of $1.05 billion, or $4.01 a share, compared with $1.04 billion, or $3.97 a share, for the same period a year earlier.
  

• Vertex Pharmaceuticals Q3 Non-GAAP Profit, Revenue Rise; 2024 Revenue Outlook Updated, from 3 hours ago by MT Newswires

  3 hours ago by MT Newswires
  Companies Mentioned: VRTX
  04:17 PM EST, 11/04/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) reported Q3 non-GAAP net income late Monday of $4.38 per diluted share, up from $4.08 a year earlier. Analysts polled by Capital IQ expected $4.13. Product revenue for the quar...

• -- Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Posts Q3 EPS $4.38, from 3 hours ago by MT Newswires

  3 hours ago by MT Newswires
  Companies Mentioned: VRTX
  04:03 PM EST, 11/04/2024 (MT Newswires) -- ...

• --Vertex Pharmaceuticals Raises Full Year 2024 Product Revenue Guidance to $10.8-$10.9 Billion, vs Prior View of $10.65-$10.85 Billion, from 3 hours ago by MT Newswires

  3 hours ago by MT Newswires
  Companies Mentioned: VRTX
  04:03 PM EST, 11/04/2024 (MT Newswires) -- Price: 468.00, Change: -3.12, Percent Change: -0.66 ...

• Vertex Reports Third Quarter 2024 Financial Results, from 3 hours ago by Dow Jones

  3 hours ago by Dow Jones
  Companies Mentioned: VRTX
  
  differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the company's expectations regarding its 2024 full-year product revenues, expenses and effective tax rates may be incorrect (including because one or more of the company's assumptions underlying its expectations may not be realized), that the company may not be able to receive adequate reimbursement for CASGEVY on the expected timeline, or at all, that we are unable to successfully obtain approval or commercialize suzetrigine as a treatment for acute pain or the vanzacaftor triple for CF, that external factors may have different or more significant impacts on the company's business or operations than the company currently expects, that data from preclinical testing or clinical trials, especially if based on a limited number of patients, may not be indicative of final results or available on anticipated timelines, that patient enrollment in the company's trials may be delayed, that the company may not realize the anticipated benefits from collaborations with third parties, that data from the company's development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy or other reasons, and that anticipated commercial launches may be delayed, if they occur at all. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Vertex's business, particularly those risks listed under the heading "Risk Factors" and the other cautionary factors discussed in Vertex's periodic reports filed with the SEC, including Vertex's annual report on Form 10-K for the year ended December 31, 2023, and its quarterly reports on Form 10-Q and current reports on Form 8-K, all of which are filed with the Securities and Exchange Commission (SEC) and available through the company's website at www.vrtx.com and on the SEC's website at www.sec.gov. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.